ADC Therapeutics SA Cash Flows From Used In Financing Activities
ADC Therapeutics SA (ADCT) reported Cash Flows From Used In Financing Activities of $72.24 million for the 9-month period ending 2023-09-30, per its 6-K filed 2023-11-07.
Discontinued › Cash Flow › Financing Activities
ifrs-full:CashFlowsFromUsedInFinancingActivities · last filed 2023-11-07
- ADC Therapeutics SA cash flows from used in financing activities for the quarter ending 2023-09-30 was -$2.31M, a 197.55% decline year-over-year.
- ADC Therapeutics SA cash flows from used in financing activities for the quarter ending 2023-06-30 was $74.74M.
- ADC Therapeutics SA cash flows from used in financing activities for the quarter ending 2023-03-31 was -$196.00K.
- ADC Therapeutics SA cash flows from used in financing activities for the quarter ending 2022-12-31 was -$2.45M.
| Period end | Cash Flows From Used In Financing Activities 3 month | Cash Flows From Used In Financing Activities 6 month | Cash Flows From Used In Financing Activities 9 month | Cash Flows From Used In Financing Activities 12 month |
|---|---|---|---|---|
| 2023-09-30 | -$2.31M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $72.43M derived: sum of 2 quarters · filed 2023-11-07 | $72.24M 6-K · filed 2023-11-07 | $69.79M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | $74.74M derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | $74.54M 6-K · filed 2023-08-08 | $72.09M derived: sum of 3 quarters · filed 2023-08-08 | $74.46M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-03-31 | -$196.00K 6-K · filed 2023-05-09 | -$2.64M derived: sum of 2 quarters · filed 2023-05-09 | -$279.00K derived: sum of 3 quarters · filed 2023-11-07 | -$531.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-12-31 | -$2.45M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | -$83.00K derived: sum of 2 quarters · filed 2023-11-07 | -$335.00K derived: sum of 3 quarters · filed 2023-11-07 | -$593.00K 20-F · filed 2023-03-15 |
| 2022-09-30 | $2.37M derived: 6-K 9 month − 6-K 6 month · filed 2023-11-07 | $2.11M derived: sum of 2 quarters · filed 2023-11-07 | $1.85M 6-K · filed 2023-11-07 | $637.00K derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$252.00K derived: 6-K 6 month − 6-K 3 month · filed 2023-08-08 | -$510.00K 6-K · filed 2023-08-08 | -$1.73M derived: sum of 3 quarters · filed 2023-08-08 | $217.58M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$258.00K 6-K · filed 2023-05-09 | -$1.48M derived: sum of 2 quarters · filed 2023-05-09 | $217.83M derived: sum of 3 quarters · filed 2023-05-09 | $267.43M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$1.22M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $218.09M derived: sum of 2 quarters · filed 2023-03-15 | $267.69M derived: sum of 3 quarters · filed 2023-03-15 | $267.39M 20-F · filed 2023-03-15 |
| 2021-09-30 | $219.30M derived: 6-K 9 month − 6-K 6 month · filed 2022-11-08 | $268.91M derived: sum of 2 quarters · filed 2022-11-08 | $268.61M 6-K · filed 2022-11-08 | $265.74M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-06-30 | $49.60M derived: 6-K 6 month − 6-K 3 month · filed 2022-08-09 | $49.31M 6-K · filed 2022-08-09 | $46.44M derived: sum of 3 quarters · filed 2023-03-15 | $237.72M derived: sum of 4 quarters · filed 2023-03-15 |
| 2021-03-31 | -$297.00K 6-K · filed 2022-05-09 | -$3.17M derived: sum of 2 quarters · filed 2023-03-15 | $188.11M derived: sum of 3 quarters · filed 2023-03-15 | $494.95M derived: sum of 4 quarters · filed 2023-03-15 |
| 2020-12-31 | -$2.87M derived: 20-F 12 month − 6-K 9 month · filed 2023-03-15 | $188.41M derived: sum of 2 quarters · filed 2023-03-15 | $495.24M derived: sum of 3 quarters · filed 2023-03-15 | $494.97M 20-F · filed 2023-03-15 |
| 2020-09-30 | $191.28M derived: 6-K 9 month − 6-K 6 month · filed 2021-11-02 | $498.12M derived: sum of 2 quarters · filed 2021-11-02 | $497.84M 6-K · filed 2021-11-02 | |
| 2020-06-30 | $306.83M derived: 6-K 6 month − 6-K 3 month · filed 2021-08-03 | $306.56M 6-K · filed 2021-08-03 | ||
| 2020-03-31 | -$278.00K 6-K · filed 2021-05-06 | |||
| 2019-12-31 | $100.51M 20-F · filed 2022-03-17 | |||
| 2018-12-31 | -$24.00K 20-F · filed 2021-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |